Beigene Ltd
HKEX:6160

Watchlist Manager
Beigene Ltd Logo
Beigene Ltd
HKEX:6160
Watchlist
Price: 106 HKD -0.09%
Market Cap: 144.4B HKD
Have any thoughts about
Beigene Ltd?
Write Note

Beigene Ltd
Inventory

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Beigene Ltd
Inventory Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Inventory CAGR 3Y CAGR 5Y CAGR 10Y
Beigene Ltd
HKEX:6160
Inventory
ÂĄ3B
CAGR 3-Years
72%
CAGR 5-Years
92%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Inventory
ÂĄ690.4m
CAGR 3-Years
-14%
CAGR 5-Years
24%
CAGR 10-Years
N/A
Akeso Inc
HKEX:9926
Inventory
ÂĄ341.8m
CAGR 3-Years
77%
CAGR 5-Years
82%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Inventory
ÂĄ905.5m
CAGR 3-Years
31%
CAGR 5-Years
33%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Inventory
ÂĄ15.7B
CAGR 3-Years
33%
CAGR 5-Years
43%
CAGR 10-Years
57%
Imeik Technology Development Co Ltd
SZSE:300896
Inventory
ÂĄ49.8m
CAGR 3-Years
23%
CAGR 5-Years
31%
CAGR 10-Years
N/A
No Stocks Found

Beigene Ltd
Glance View

Market Cap
146.2B HKD
Industry
Biotechnology

BeiGene Ltd., a biopharmaceutical company with origins in Beijing, stands as a prominent player in the global fight against cancer. Founded in 2010, BeiGene has strategically positioned itself as an innovator in the field of oncology, focusing on molecularly targeted and immuno-oncology drug candidates. The company’s journey began with the vision to challenge the conventional barriers to cancer treatment, particularly in emerging markets where access to advanced therapeutics was limited. Its pipeline, robust with both internally developed and in-licensed candidates, reflects an ambitious approach to tackling various forms of cancer, including but not limited to hematological malignancies and solid tumors. The company generates revenue by developing, manufacturing, and commercializing innovative cancer therapies. BeiGene's business model is multifaceted; it involves in-house development and collaborations with international pharmaceutical giants. A significant portion of its revenue is derived from strategic partnerships, such as co-development and commercialization agreements, which allow the company to expand its market reach. Moreover, BeiGene invests heavily in research and development, which not only drives the discovery of new therapies but also strengthens its competitive edge in the pharmaceutical landscape. By balancing scientific advancement with keen market strategies, BeiGene aims to bridge the gap in global cancer care, aspiring to make life-saving treatments accessible to more patients across diverse geographies.

Intrinsic Value
177.75 HKD
Undervaluation 40%
Intrinsic Value
Price

See Also

What is Beigene Ltd's Inventory?
Inventory
3B CNY

Based on the financial report for Dec 31, 2023, Beigene Ltd's Inventory amounts to 3B CNY.

What is Beigene Ltd's Inventory growth rate?
Inventory CAGR 5Y
92%

Over the last year, the Inventory growth was 51%. The average annual Inventory growth rates for Beigene Ltd have been 72% over the past three years , 92% over the past five years .

Back to Top